Korsana Biosciences, Inc. (KRSA)
| Market Cap | 1.42B +27,168.2% |
| Revenue (ttm) | n/a |
| Net Income | -49.08M |
| EPS | -13.37 |
| Shares Out | 45.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 383,991 |
| Open | 31.00 |
| Previous Close | 31.17 |
| Day's Range | 30.00 - 32.30 |
| 52-Week Range | 7.19 - 59.36 |
| Beta | 1.84 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+41.43%) |
| Earnings Date | Nov 5, 2026 |
About KRSA
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for KRSA stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 41.43% from the latest price.
News
Korsana Biosciences Transcript: Stifel 2026 Healthcare Conference 2026
KRSA-028 is designed as a monthly subQ, pyroglutamate-targeting amyloid shuttle, with preclinical design choices aimed at retaining plaque clearance while reducing safety risks. Healthy-volunteer data are targeted for mid-2027, with patient proof-of-concept by late 2027 or Q1 2028.
Korsana Biosciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
KRSA-028 combines a brain shuttle, modified effector function and subcutaneous dosing, with the goal of improving convenience and safety while retaining plaque clearance. CTA is planned by end-2026, with SAD data expected mid-2027.
Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer'...
Korsana Biosciences Earnings release: Q3 2026
Korsana Biosciences released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Korsana Biosciences Quarterly report: Q3 2026
Korsana Biosciences has published its Q3 2026 quarterly earnings report on November 5, 2026.
Korsana Biosciences to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”) (Nasdaq: KRSA), a biotechnology company discovering and developing novel therapies to reduce th...
Korsana Biosciences Proxy statement: Proxy filing
Korsana Biosciences filed a proxy statement on October 15, 2026, providing details for shareholder voting and corporate governance matters.
Korsana Biosciences initiated with a Buy at Guggenheim on KRSA-028 potential
As previously reported, Guggenheim analyst Yatin Suneja initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target. KRSA-028 is a second-generation monoclonal antibody del...
Korsana Biosciences Proxy statement: Proxy filing
Korsana Biosciences filed a proxy statement on October 5, 2026, providing details for shareholder voting and corporate governance matters.
Wedbush starts Korsana at Outperform on Alzheimer’s potential
Wedbush analyst Laura Chico initiated coverage of Korsana Biosciences (KRSA) with an Outperform rating and $44 price target The firm believes the company’s next-generation anti-amyloid-C KRSA-028 offe...
Korsana Biosciences initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico initiated coverage of Korsana Biosciences (KRSA) with an Outperform rating and $44 price target
Korsana Biosciences initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target KRSA-028 is a second-generation shuttled anti-Abeta monoclonal antibody built on the proprietary THET...
Korsana Biosciences initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target
Korsana Biosciences initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and no price target The firm believes the company has the superior brain shuttle technology for Alzheimer’s disease.
Korsana Biosciences initiated with a Buy at Stifel
Stifel initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $43 price target Korsana is a neuroscience focused biotech company that is pioneering the advancement of multiple drug…
UBS starts Korsana Biosciences at Buy on Alzheimer’s potential
UBS last night initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $55 price target The firm views the company’s lead asset KRSA-028 as a potential “best-in-class” treatment…
Korsana Biosciences initiated with a Buy at UBS
UBS initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $55 price target